OUTCOMES OF PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS IN PATIENTS TREATED UPFRONT WITH BORTEZOMIB OR LENALIDOMIDE AND THE IMPORTANCE OF RISK ADAPTED STRATEGIES
OUTCOMES OF PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS IN PATIENTS TREATED UPFRONT WITH BORTEZOMIB OR LENALIDOMIDE AND THE IMPORTANCE OF RISK ADAPTED STRATEGIES
Kastritis, E
Roussou, M
Gavriatopoulou, M
Migkou, M
Pamboucas, C
Kaldara, E
Ntalianis, A
Psimenou, E
Toumanidis, S
Terpos, E
others
*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)
OUTCOMES OF PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS IN PATIENTS TREATED UPFRONT WITH BORTEZOMIB OR LENALIDOMIDE AND THE IMPORTANCE OF RISK ADAPTED STRATEGIES
OUTCOMES OF PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS IN PATIENTS TREATED UPFRONT WITH BORTEZOMIB OR LENALIDOMIDE AND THE IMPORTANCE OF RISK ADAPTED STRATEGIES
Βοηθείστε μας να κάνουμε καλύτερο το OpenArchives.gr.